Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2024 Financial Results
1. Fourth quarter 2024 sales reached $873 million, up 6% year-over-year. 2. Pharmaceutical sales grew by 10% in constant currency, boosting overall growth. 3. Non-GAAP EPS rose to $4.10, surpassing analysts' expectations despite currency headwinds. 4. 2025 full-year sales guidance estimates growth of 2.5% to 5%. 5. Waters maintained a strong operational margin, indicating robust business resilience.